- Age ≥ 18 years
- Patients with advanced or metastatic renal cell carcinoma, histologically
confirmed, with at least one radiological response assessment
- Patients who had received Axitinib treatment in second or further line with a PFS
≥9 months or DP (disease progression) at the first tumor assessment.
- For the patients alive at the moment of the inclusion, patients must have a
signed informed consent document
- Axitinib received out of the approved indication Patients who do not meet any of the